Patients with neurologic involvement had significantly higher odds of receiving eculizumab therapy than those without (odds ratio, 13.03; 95% CI, 4.40-38.75); 74.5% of patients in the eculizumab ...

A dedicated onconephrology service at Brigham and Women’s Hospital has improved kidney outcomes in patients treated for ...

Soliris (eculizumab) is a treatment for atypical haemolytic uraemic syndrome (aHUS) developed and marketed by Alexion. aHUS is a very rare disease, with around 140 patients diagnosed in England.

That covers all of the FDA-approved indications for Soliris (eculizumab), except for neuromyelitis optica spectrum disorder (NMOSD) which remains protected by use patents. The US launch of the two ...

President Trump touted a new Executive Order that would more closely align drug prices in the US with those sold in Europe ...

Meningococcal vaccines protect against bacterial infections caused by Neisseria meningitidis. These bacteria are capable of causing meningococcal meningitis, a condition that causes inflammation of ...

Paroxysmal nocturnal hemoglobinuria (PNH) is an acquired, potentially life-threatening disorder linked to a specific gene. It can occur at any age but most often is diagnosed in young adults. PNH ...